Literature DB >> 23765697

Alternative RNA splicing and cancer.

Sali Liu1, Chonghui Cheng.   

Abstract

Alternative splicing of pre-messenger RNA (mRNA) is a fundamental mechanism by which a gene can give rise to multiple distinct mRNA transcripts, yielding protein isoforms with different, even opposing, functions. With the recognition that alternative splicing occurs in nearly all human genes, its relationship with cancer-associated pathways has emerged as a rapidly growing field. In this review, we summarize recent findings that have implicated the critical role of alternative splicing in cancer and discuss current understandings of the mechanisms underlying dysregulated alternative splicing in cancer cells.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23765697      PMCID: PMC4426271          DOI: 10.1002/wrna.1178

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev RNA        ISSN: 1757-7004            Impact factor:   9.957


  225 in total

1.  SF2 and SRp55 regulation of CD45 exon 4 skipping during T cell activation.

Authors:  R Lemaire; A Winne; M Sarkissian; R Lafyatis
Journal:  Eur J Immunol       Date:  1999-03       Impact factor: 5.532

Review 2.  Role of protein tyrosine phosphatases in T cell activation.

Authors:  Tomas Mustelin; Souad Rahmouni; Nunzio Bottini; Andres Alonso
Journal:  Immunol Rev       Date:  2003-02       Impact factor: 12.988

3.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

4.  Evidence for an alternative glycolytic pathway in rapidly proliferating cells.

Authors:  Matthew G Vander Heiden; Jason W Locasale; Kenneth D Swanson; Hadar Sharfi; Greg J Heffron; Daniel Amador-Noguez; Heather R Christofk; Gerhard Wagner; Joshua D Rabinowitz; John M Asara; Lewis C Cantley
Journal:  Science       Date:  2010-09-17       Impact factor: 47.728

Review 5.  Regulation of apoptosis by alternative pre-mRNA splicing.

Authors:  Christian Schwerk; Klaus Schulze-Osthoff
Journal:  Mol Cell       Date:  2005-07-01       Impact factor: 17.970

Review 6.  Evolution of SR protein and hnRNP splicing regulatory factors.

Authors:  Anke Busch; Klemens J Hertel
Journal:  Wiley Interdiscip Rev RNA       Date:  2011-09-02       Impact factor: 9.957

7.  Influence of polymerase II processivity on alternative splicing depends on splice site strength.

Authors:  Guadalupe Nogués; Manuel J Muñoz; Alberto R Kornblihtt
Journal:  J Biol Chem       Date:  2003-10-06       Impact factor: 5.157

8.  An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype.

Authors:  Irina M Shapiro; Albert W Cheng; Nicholas C Flytzanis; Michele Balsamo; John S Condeelis; Maja H Oktay; Christopher B Burge; Frank B Gertler
Journal:  PLoS Genet       Date:  2011-08-18       Impact factor: 5.917

9.  TGF-β drives epithelial-mesenchymal transition through δEF1-mediated downregulation of ESRP.

Authors:  K Horiguchi; K Sakamoto; D Koinuma; K Semba; A Inoue; S Inoue; H Fujii; A Yamaguchi; K Miyazawa; K Miyazono; M Saitoh
Journal:  Oncogene       Date:  2011-10-31       Impact factor: 9.867

10.  Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.

Authors:  Andrea Prodosmo; Simona Giglio; Sonia Moretti; Francesca Mancini; Flavia Barbi; Nicola Avenia; Giusy Di Conza; Holger J Schünemann; Lorenza Pistola; Vienna Ludovini; Ada Sacchi; Alfredo Pontecorvi; Efisio Puxeddu; Fabiola Moretti
Journal:  J Mol Med (Berl)       Date:  2008-03-12       Impact factor: 4.599

View more
  50 in total

1.  Methods for Characterization of Alternative RNA Splicing.

Authors:  Samuel E Harvey; Chonghui Cheng
Journal:  Methods Mol Biol       Date:  2016

Review 2.  Alternative splicing as a biomarker and potential target for drug discovery.

Authors:  Kai-qin Le; Bellur S Prabhakar; Wan-jin Hong; Liang-cheng Li
Journal:  Acta Pharmacol Sin       Date:  2015-06-15       Impact factor: 6.150

3.  Detection of alternative splicing during epithelial-mesenchymal transition.

Authors:  Huilin Huang; Yilin Xu; Chonghui Cheng
Journal:  J Vis Exp       Date:  2014-10-09       Impact factor: 1.355

4.  "RADIOTRANSCRIPTOMICS": A synergy of imaging and transcriptomics in clinical assessment.

Authors:  Amal Katrib; William Hsu; Alex Bui; Yi Xing
Journal:  Quant Biol       Date:  2016-03-04

5.  Cancer Explant Models.

Authors:  Christian T Stackhouse; George Yancey Gillespie; Christopher D Willey
Journal:  Curr Top Microbiol Immunol       Date:  2021       Impact factor: 4.291

6.  Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models.

Authors:  Rocco Sciarrillo; Anna Wojtuszkiewicz; Irsan E Kooi; Valentina E Gómez; Ugo Boggi; Gerrit Jansen; Gert-Jan Kaspers; Jacqueline Cloos; Elisa Giovannetti
Journal:  J Vis Exp       Date:  2016-12-09       Impact factor: 1.355

Review 7.  Gene Regulatory Network Perturbation by Genetic and Epigenetic Variation.

Authors:  Yongsheng Li; Daniel J McGrail; Juan Xu; Gordon B Mills; Nidhi Sahni; Song Yi
Journal:  Trends Biochem Sci       Date:  2018-06-22       Impact factor: 13.807

8.  Aberrant RNA splicing and mutations in spliceosome complex in acute myeloid leukemia.

Authors:  Jianbiao Zhou; Wee-Joo Chng
Journal:  Stem Cell Investig       Date:  2017-02-09

9.  Akt Signaling Is Sustained by a CD44 Splice Isoform-Mediated Positive Feedback Loop.

Authors:  Sali Liu; Chonghui Cheng
Journal:  Cancer Res       Date:  2017-05-22       Impact factor: 12.701

Review 10.  Cytokine receptor splice variants in hematologic diseases.

Authors:  Borwyn Wang; Hrishikesh Mehta
Journal:  Cytokine       Date:  2019-12-06       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.